BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 26453145)

  • 1. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis.
    Huo YR; Richards A; Liauw W; Morris DL
    Eur J Surg Oncol; 2015 Dec; 41(12):1578-89. PubMed ID: 26453145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
    Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
    Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis.
    Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
    Eur J Surg Oncol; 2019 Mar; 45(3):301-309. PubMed ID: 30786961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
    Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
    Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
    Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.
    Baiocchi G; Ferreira FO; Mantoan H; da Costa AA; Faloppa CC; Kumagai LY; de Mello CA; Takahashi RM; Nakagawa WT; Aguiar S; Lopes A
    Ann Surg Oncol; 2016 Apr; 23(4):1294-301. PubMed ID: 26628430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.
    Bouchard-Fortier G; Cusimano MC; Fazelzad R; Sajewycz K; Lu L; Espin-Garcia O; May T; Bouchard-Fortier A; Ferguson SE
    Gynecol Oncol; 2020 Jul; 158(1):218-228. PubMed ID: 32387131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laparoscopic versus open approach for interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced epithelial ovarian cancer: a matched comparative study.
    Durán-Martínez M; Gómez-Dueñas G; Rodriguez-Ortíz L; Sanchez-Hidalgo JM; Gordón-Suárez A; Casado-Adam Á; Rufián-Peña S; Valenzuela-Molina F; Rufián-Andujar B; Vázquez-Borrego MC; Romero-Ruiz A; Briceño-Delgado J; Arjona-Sánchez Á
    Surg Endosc; 2024 Jan; 38(1):66-74. PubMed ID: 37903884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Zambrano-Vera K; Sardi A; Lopez-Ramirez F; Sittig M; Munoz-Zuluaga C; Nieroda C; Gushchin V; Diaz-Montes T
    Ann Surg Oncol; 2021 Aug; 28(8):4655-4666. PubMed ID: 33393042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
    Kim SI; Kim JH; Lee S; Cho H; van Driel WJ; Sonke GS; Bristow RE; Park SY; Fotopoulou C; Lim MC
    Gynecol Oncol; 2022 Dec; 167(3):547-556. PubMed ID: 36273925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
    Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
    Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.
    Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P
    Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial and recurrent ovarian carcinoma: a single center experience.
    Pavlov MJ; Ceranic MS; Latincic SM; Sabljak PV; Kecmanovic DM; Sugarbaker PH
    Int J Hyperthermia; 2018 Aug; 34(5):564-569. PubMed ID: 28877609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer.
    Halkia E; Spiliotis J
    J BUON; 2015 May; 20 Suppl 1():S12-28. PubMed ID: 26051328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
    Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperthermic intraperitoneal chemoperfusion as a component of multimodality therapy for ovarian and primary peritoneal cancer.
    Magge D; Ramalingam L; Shuai Y; Edwards RP; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL; Choudry HA
    J Surg Oncol; 2017 Sep; 116(3):320-328. PubMed ID: 28628712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients.
    Bakrin N; Bereder JM; Decullier E; Classe JM; Msika S; Lorimier G; Abboud K; Meeus P; Ferron G; Quenet F; Marchal F; Gouy S; Morice P; Pomel C; Pocard M; Guyon F; Porcheron J; Glehen O;
    Eur J Surg Oncol; 2013 Dec; 39(12):1435-43. PubMed ID: 24209430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer.
    de Bree E; Michelakis D
    Expert Opin Pharmacother; 2020 Aug; 21(12):1479-1492. PubMed ID: 32486865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as a treatment for recurrent epithelial ovarian cancer-National Cancer Institute experience.
    Fahim MI; Nassar OA; Mansour OM; Ali AM; Mahmoud AM; Allam RM; Kamal A
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):139-141. PubMed ID: 30470604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.